Recurrent pregnancy loss (RPL) is a dreadful reproductive health burden that affects around 5% of couples worldwide who are trying to conceive. Luteal phase insufficiency is one of the factors that contribute to implantation failure and has been linked to miscarriages and unsuccessful assisted reproduction. Before the placenta assumes control of progesterone synthesis, the corpus luteum produces enough progesterone that leads to secretory changes in the endometrium to maintain early pregnancy. A deficiency in corpus luteum function is linked with implantation failure and ends up in miscarriage. The optimum period for implantation is 6–10 days following the peak of luteinizing hormone (LH); any earlier or later than this is linked to an increased chance of miscarriage. Women with polycystic ovaries, thyroid, and prolactin disorders frequently have luteal phase defects. Women with a history of recurrent miscarriage (RM) have been found to benefit from the treatment of the underlying disease and the use of progestational hormones like progesterone and human chorionic gonadotrophin. There are more uterine and peripheral natural killer (NK) cells in women who experience RM than in control women, according to several publications. However, there is no evidence linking it to miscarriage. The goal of the current study is to thoroughly assess luteal phase steroids in cases of unexplained miscarriage. The patients were split up into two groups for this study. Group I received progesterone with Deltacortril while group II received progesterone treatment.